公司比较
并排比较供应链位置、机构信号和新闻间隙评分。
市值区间
链条角色
间隙评分
IB活动
营收结构比较
简介
Eli Lilly is the world's most valuable pharmaceutical company, propelled by the blockbuster GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound) for diabetes and obesity. Its Alzheimer's antibody donanemab and strong oncology pipeline give it one of the most promising drug portfolios in the industry.
成立时间
1876
员工人数
43,000+
总部
Indianapolis, Indiana, USA
营收
$52.8B
新闻缺口信号
此股票代码没有新闻缺口数据。
机构信号
此代码没有13F信号记录。
关键关系
简介
Novo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.
成立时间
1923
员工人数
64,000+
总部
Bagsvaerd, Denmark
营收
$42.6B
新闻缺口信号
此股票代码没有新闻缺口数据。
机构信号
此代码没有13F信号记录。